# Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

> **NCT03660683** · PHASE4 · TERMINATED · sponsor: **Sabyasachi Sen** · enrollment: 15 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Cardiovascular Diseases

## Interventions

- **DRUG:** Dapagliflozin 10mg
- **DRUG:** Saxagliptin 5mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03660683
- **Lead sponsor:** Sabyasachi Sen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-22
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-12-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor did not want to continue funding the study
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03660683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03660683, "Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03660683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*